CEACAM7
gene geneOn this page
Also known as CEA
Summary
CEACAM7 (CEA cell adhesion molecule 7, HGNC:1819) is a protein-coding gene on chromosome 19q13.2, encoding Cell adhesion molecule CEACAM7 (Q14002).
This gene encodes a cell surface glycoprotein and member of the carcinoembryonic antigen (CEA) family of proteins. Expression of this gene may be downregulated in colon and rectal cancer. Additionally, lower expression levels of this gene may be predictive of rectal cancer recurrence. This gene is present in a CEA family gene cluster on chromosome 19. Alternative splicing results in multiple transcript variants.
Source: NCBI Gene 1087 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 47 total
- GTEx eGene: eQTL in 7 tissues, sQTL in 0 (q < 0.05)
- Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.37 (unconstrained)
- MANE Select transcript:
NM_001291485
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:1819 |
| Approved symbol | CEACAM7 |
| Name | CEA cell adhesion molecule 7 |
| Location | 19q13.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | CEA |
| Ensembl gene | ENSG00000007306 |
| Ensembl biotype | protein_coding |
| OMIM | 619160 |
| Entrez | 1087 |
Gene structure
Transcript identifiers
Ensembl transcripts: 21 — 17 protein_coding, 3 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined
MANE Select: ENST00000401731
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 2: 1, TSL 5: 1
ENST00000401731, ENST00000006724, ENST00000599715, ENST00000602225, ENST00000869051, ENST00000869052, ENST00000869053, ENST00000869054, ENST00000869055, ENST00000869056, ENST00000869057, ENST00000869058, ENST00000869059, ENST00000869060, ENST00000869061, ENST00000948635, ENST00000994563, ENST00000994564, ENST00001022527, ENST00001022533, ENST00001134003
RefSeq mRNA: 2 — MANE Select: NM_001291485
NM_001291485, NM_006890
CCDS: CCDS12583
Canonical transcript exons
ENST00000401731 — 5 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000842466 | 41677376 | 41677503 |
| ENSE00001555472 | 41688102 | 41688270 |
| ENSE00001560913 | 41673303 | 41674739 |
| ENSE00002517916 | 41683785 | 41684063 |
| ENSE00003495567 | 41686859 | 41687221 |
Expression profiles
Bgee: expression breadth ubiquitous, 137 present calls, max score 99.62.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.9852 / max 1201.3699, expressed in 35 samples.
Highest expression (Bgee): mucosa of transverse colon, rectum, colonic mucosa, mucosa of sigmoid colon, ileal mucosa.
Genetic regulation across tissues (GTEx eQTL / sQTL)
CEACAM7 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 7 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
7 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Esophagus Mucosa | eqtl | 7.3e-34 | -0.38 | 19:41675017:C:G |
| Skin Sun Exposed Lower leg | eqtl | 2.6e-23 | +0.42 | 19:41642531:C:A |
| Skin Not Sun Exposed Suprapubic | eqtl | 4.3e-15 | +0.39 | 19:41654540:T:TA |
| Colon Transverse | eqtl | 9.6e-06 | -0.15 | 19:41662744:T:C |
| Pancreas | eqtl | 4.9e-04 | -0.27 | 19:41685453:T:C |
| Whole Blood | eqtl | 7.8e-03 | +0.45 | 19:40774896:G:A |
| Prostate | eqtl | 1.8e-02 | +0.41 | 19:41247729:G:A |
FANTOM5 promoters
2 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 181085 | 0.8573 | 35 |
| 181084 | 0.1279 | 12 |
Top tissues by expression
showing 100 of 267 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| mucosa of transverse colon | UBERON:0004991 | 99.62 | gold quality |
| rectum | UBERON:0001052 | 99.61 | gold quality |
| colonic mucosa | UBERON:0000317 | 99.32 | gold quality |
| mucosa of sigmoid colon | UBERON:0004993 | 99.17 | gold quality |
| ileal mucosa | UBERON:0000331 | 93.00 | gold quality |
| vermiform appendix | UBERON:0001154 | 92.61 | gold quality |
| transverse colon | UBERON:0001157 | 91.47 | gold quality |
| islet of Langerhans | UBERON:0000006 | 89.42 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 89.37 | gold quality |
| gall bladder | UBERON:0002110 | 88.67 | gold quality |
| esophagus mucosa | UBERON:0002469 | 85.96 | gold quality |
| caecum | UBERON:0001153 | 85.29 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 84.95 | gold quality |
| diaphragm | UBERON:0001103 | 79.56 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 79.55 | gold quality |
| large intestine | UBERON:0000059 | 79.13 | gold quality |
| colon | UBERON:0001155 | 78.37 | gold quality |
| vagina | UBERON:0000996 | 77.96 | gold quality |
| cervix epithelium | UBERON:0004801 | 77.53 | gold quality |
| pancreatic ductal cell | CL:0002079 | 77.32 | silver quality |
| epithelium of esophagus | UBERON:0001976 | 76.26 | gold quality |
| oral cavity | UBERON:0000167 | 75.90 | gold quality |
| esophagus squamous epithelium | UBERON:0006920 | 75.86 | gold quality |
| colonic epithelium | UBERON:0000397 | 75.23 | gold quality |
| cervix squamous epithelium | UBERON:0006922 | 73.79 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 71.26 | silver quality |
| olfactory bulb | UBERON:0002264 | 71.09 | gold quality |
| pancreas | UBERON:0001264 | 70.93 | gold quality |
| squamous epithelium | UBERON:0006914 | 70.58 | gold quality |
| intestine | UBERON:0000160 | 70.33 | gold quality |
| pharyngeal mucosa | UBERON:0000355 | 70.21 | gold quality |
| mucosa of urinary bladder | UBERON:0001259 | 70.14 | gold quality |
| type B pancreatic cell | CL:0000169 | 67.40 | gold quality |
| hair follicle | UBERON:0002073 | 65.94 | gold quality |
| esophagus | UBERON:0001043 | 65.21 | gold quality |
| uterine cervix | UBERON:0000002 | 64.11 | gold quality |
| oviduct epithelium | UBERON:0004804 | 63.85 | gold quality |
| body of pancreas | UBERON:0001150 | 63.27 | gold quality |
| skeletal muscle tissue of biceps brachii | UBERON:0004502 | 62.62 | gold quality |
| tongue squamous epithelium | UBERON:0006919 | 62.43 | gold quality |
| ectocervix | UBERON:0012249 | 61.17 | gold quality |
| jejunal mucosa | UBERON:0000399 | 60.30 | gold quality |
| tonsil | UBERON:0002372 | 59.87 | gold quality |
| decidua | UBERON:0002450 | 58.52 | gold quality |
| gluteal muscle | UBERON:0002000 | 58.47 | gold quality |
| quadriceps femoris | UBERON:0001377 | 58.33 | gold quality |
| triceps brachii | UBERON:0001509 | 58.29 | gold quality |
| tongue | UBERON:0001723 | 58.28 | silver quality |
| smooth muscle tissue | UBERON:0001135 | 58.19 | gold quality |
| upper arm skin | UBERON:0004263 | 58.13 | gold quality |
| vastus lateralis | UBERON:0001379 | 58.12 | gold quality |
| skin of abdomen | UBERON:0001416 | 57.99 | gold quality |
| mucosa of paranasal sinus | UBERON:0005030 | 57.68 | gold quality |
| duodenum | UBERON:0002114 | 57.48 | gold quality |
| amniotic fluid | UBERON:0000173 | 57.30 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 57.04 | gold quality |
| gingiva | UBERON:0001828 | 56.84 | gold quality |
| urinary bladder | UBERON:0001255 | 56.50 | gold quality |
| mammary duct | UBERON:0001765 | 56.46 | gold quality |
| epithelium of mammary gland | UBERON:0003244 | 56.10 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 56.05 | gold quality |
| zone of skin | UBERON:0000014 | 55.68 | gold quality |
| skin of leg | UBERON:0001511 | 55.30 | gold quality |
| right coronary artery | UBERON:0001625 | 55.16 | gold quality |
| jejunum | UBERON:0002115 | 54.64 | gold quality |
| thymus | UBERON:0002370 | 53.84 | gold quality |
| superior surface of tongue | UBERON:0007371 | 53.34 | gold quality |
| mouth mucosa | UBERON:0003729 | 52.97 | gold quality |
| minor salivary gland | UBERON:0001830 | 52.84 | gold quality |
| endothelial cell | CL:0000115 | 52.81 | gold quality |
| deltoid | UBERON:0001476 | 52.78 | gold quality |
| gingival epithelium | UBERON:0001949 | 52.63 | gold quality |
| muscle tissue | UBERON:0002385 | 52.22 | gold quality |
| fallopian tube | UBERON:0003889 | 52.21 | gold quality |
| substantia nigra pars reticulata | UBERON:0001966 | 52.15 | gold quality |
| Brodmann (1909) area 46 | UBERON:0006483 | 51.77 | gold quality |
| heart right ventricle | UBERON:0002080 | 51.76 | gold quality |
| upper leg skin | UBERON:0004262 | 51.76 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 51.28 | gold quality |
| orbitofrontal cortex | UBERON:0004167 | 50.54 | gold quality |
| kidney epithelium | UBERON:0004819 | 50.25 | gold quality |
| myocardium | UBERON:0002349 | 50.22 | gold quality |
| CA1 field of hippocampus | UBERON:0003881 | 50.18 | gold quality |
| substantia nigra pars compacta | UBERON:0001965 | 49.96 | gold quality |
| nasal cavity mucosa | UBERON:0001826 | 49.79 | gold quality |
| lateral nuclear group of thalamus | UBERON:0002736 | 49.56 | gold quality |
| cardiac muscle of right atrium | UBERON:0003379 | 49.29 | gold quality |
| blood vessel layer | UBERON:0004797 | 49.29 | gold quality |
| bone marrow | UBERON:0002371 | 49.12 | gold quality |
| skin of hip | UBERON:0001554 | 48.97 | silver quality |
| choroid plexus epithelium | UBERON:0003911 | 48.89 | gold quality |
| left ventricle myocardium | UBERON:0006566 | 48.24 | gold quality |
| biceps brachii | UBERON:0001507 | 48.09 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 48.07 | gold quality |
| inferior olivary complex | UBERON:0002127 | 47.56 | gold quality |
| nephron tubule | UBERON:0001231 | 47.52 | gold quality |
| periodontal ligament | UBERON:0008266 | 47.14 | gold quality |
| urethra | UBERON:0000057 | 46.99 | silver quality |
| renal glomerulus | UBERON:0000074 | 46.99 | gold quality |
| metanephric glomerulus | UBERON:0004736 | 46.96 | gold quality |
Single-cell (SCXA)
Detected in 3 experiment(s), a significant marker in 3.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-83139 | yes | 3529.05 |
| E-GEOD-125970 | yes | 2283.47 |
| E-ANND-3 | yes | 13.54 |
HPA expression
RNA tissue specificity: Tissue enriched
31 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM | Protein (IHC) |
|---|---|---|---|
| Rectum | tissue | 612.7 | medium |
| Colon | tissue | 559.1 | medium |
| Appendix | tissue | 67.5 | medium |
| Esophagus | tissue | 49.4 | not detected |
| Gallbladder | tissue | 37.0 | not detected |
| Vagina | tissue | 34.4 | not detected |
| Urinary bladder | tissue | 21.9 | not detected |
| Tonsil | tissue | 11.3 | not detected |
| Smooth muscle | tissue | 5.3 | not detected |
| Stomach 1 | tissue | 1.9 | low |
| Pancreas | tissue | 1.4 | not detected |
| Skin 1 | tissue | 1.3 | low |
| Seminal vesicle | tissue | 0.7 | low |
| Cervix | tissue | 0.6 | not detected |
| Adipose tissue | tissue | 0.5 | not detected |
| Duodenum | tissue | 0.5 | low |
| Kidney | tissue | 0.4 | medium |
| Fallopian tube | tissue | 0.4 | not detected |
| Breast | tissue | 0.3 | medium |
| Endometrium 1 | tissue | 0.3 | not detected |
| Spleen | tissue | 0.2 | not detected |
| Testis | tissue | 0.1 | not detected |
| Salivary gland | tissue | 0.1 | low |
| Skeletal muscle | tissue | 0.1 | not detected |
| Prostate | tissue | 0.1 | not detected |
| Bone marrow | tissue | 0.1 | not detected |
| Heart muscle | tissue | 0.0 | low |
| Parathyroid gland | tissue | 0.0 | medium |
| Epididymis | tissue | 0.0 | medium |
| Placenta | tissue | 0.0 | low |
| Small intestine | tissue | 0.0 | low |
Brain sub-regions (HPA Brain Atlas): detected in 2; highest nTPM — Endometrium 2 (-1.0), Stomach 2 (-1.0).
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): GLI2
miRNA regulators (miRDB)
Targeting CEACAM7 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).
showing 30 of 59 miRNAs:
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4481 | 100.00 | 66.42 | 1669 |
| HSA-MIR-103A-3P | 99.98 | 69.14 | 1595 |
| HSA-MIR-107 | 99.98 | 69.14 | 1595 |
| HSA-MIR-4745-5P | 99.98 | 65.95 | 1028 |
| HSA-MIR-1468-3P | 99.96 | 72.74 | 3797 |
| HSA-MIR-3910 | 99.95 | 71.13 | 2227 |
| HSA-MIR-3119 | 99.92 | 71.34 | 2390 |
| HSA-MIR-4302 | 99.89 | 67.94 | 1187 |
| HSA-MIR-544A | 99.84 | 68.66 | 1965 |
| HSA-MIR-4668-5P | 99.79 | 70.58 | 3782 |
| HSA-MIR-200A-5P | 99.76 | 69.10 | 949 |
| HSA-MIR-200B-5P | 99.76 | 69.05 | 948 |
| HSA-MIR-6512-3P | 99.65 | 66.07 | 1468 |
| HSA-MIR-6720-5P | 99.65 | 66.22 | 1459 |
| HSA-MIR-1303 | 99.65 | 69.77 | 1662 |
| HSA-MIR-2053 | 99.57 | 69.15 | 1635 |
| HSA-MIR-1252-3P | 99.55 | 67.71 | 2862 |
| HSA-MIR-154-3P | 99.50 | 70.05 | 831 |
| HSA-MIR-487A-3P | 99.50 | 69.95 | 840 |
| HSA-MIR-548G-3P | 99.48 | 68.67 | 2159 |
| HSA-MIR-3123 | 99.47 | 67.15 | 2693 |
| HSA-MIR-6839-3P | 99.39 | 68.86 | 1301 |
| HSA-MIR-940 | 99.37 | 66.14 | 2064 |
| HSA-MIR-4311 | 99.31 | 70.47 | 3041 |
| HSA-MIR-6808-5P | 99.31 | 66.23 | 2150 |
| HSA-MIR-6893-5P | 99.31 | 66.25 | 2119 |
| HSA-MIR-329-5P | 99.27 | 68.11 | 1597 |
| HSA-MIR-10522-5P | 99.26 | 68.50 | 2087 |
| HSA-MIR-4263 | 99.18 | 69.25 | 2236 |
| HSA-MIR-4504 | 99.10 | 69.14 | 1328 |
Functional genomics
gnomAD constraint: pLI 2.22e-08, LOEUF 1.37, missense Z 0.264 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD
Regional missense constraint (gnomAD RMC): no regional variation along ENST00000401731 — one region, missense o/e 0.98.
Literature-anchored findings (GeneRIF, showing 6)
- CGM2 RT-PCR assay provides no specific prognostic information and cannot be used as a decision criterion for adjuvant therapy after colorectal cancer surgery. (PMID:16627067)
- CEACAM-7 expression is significantly decreased in rectal cancer; a potential tumor marker (PMID:20004437)
- High CEACAM7 is associated with gastric carcinoma. (PMID:22195770)
- crystal structure of the N-terminal dimerization domain of CEACAM has been determined at 1.47 A resolution (PMID:26323304)
- CEACAM7 expression is significantly upregulated in human masticatory mucosa during wound healing (PMID:28005267)
- CEACAM7 polymorphisms predict genetic predisposition to mortality in post-surgical septic shock patients. (PMID:34657826)
Cross-species orthologs
36 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Psg18 | ENSMUSG00000003505 |
| mus_musculus | Psg17 | ENSMUSG00000004540 |
| mus_musculus | Psg19 | ENSMUSG00000004542 |
| mus_musculus | Ceacam5 | ENSMUSG00000008789 |
| mus_musculus | Psg29 | ENSMUSG00000023159 |
| mus_musculus | Ceacam14 | ENSMUSG00000023185 |
| mus_musculus | Ceacam12 | ENSMUSG00000030366 |
| mus_musculus | Ceacam11 | ENSMUSG00000030368 |
| mus_musculus | Psg28 | ENSMUSG00000030373 |
| mus_musculus | Psg22 | ENSMUSG00000044903 |
| mus_musculus | Ceacam3 | ENSMUSG00000053228 |
| mus_musculus | Ceacam10 | ENSMUSG00000054169 |
| mus_musculus | Ceacam2 | ENSMUSG00000054385 |
| mus_musculus | Ceacam13 | ENSMUSG00000057195 |
| mus_musculus | Psg20 | ENSMUSG00000063305 |
| mus_musculus | Psg16 | ENSMUSG00000066760 |
| mus_musculus | Psg21 | ENSMUSG00000070796 |
| mus_musculus | Psg27 | ENSMUSG00000070797 |
| mus_musculus | Psg25 | ENSMUSG00000070798 |
| mus_musculus | Psg26 | ENSMUSG00000070799 |
| mus_musculus | Ceacam1 | ENSMUSG00000074272 |
| mus_musculus | Psg23 | ENSMUSG00000074359 |
| mus_musculus | Ceacam23 | ENSMUSG00000078793 |
| rattus_norvegicus | LOC102557244 | ENSRNOG00000017519 |
| rattus_norvegicus | Ceacam11 | ENSRNOG00000017620 |
| rattus_norvegicus | Ceacam1 | ENSRNOG00000020578 |
| rattus_norvegicus | Psgb1 | ENSRNOG00000027288 |
| rattus_norvegicus | Ceacam3 | ENSRNOG00000027607 |
| rattus_norvegicus | Psg29 | ENSRNOG00000029485 |
| rattus_norvegicus | LOC120098290 | ENSRNOG00000034000 |
| rattus_norvegicus | Psg19 | ENSRNOG00000038101 |
| rattus_norvegicus | Ceacam12 | ENSRNOG00000042158 |
| rattus_norvegicus | Ceacam4 | ENSRNOG00000046222 |
| rattus_norvegicus | Psg16 | ENSRNOG00000062379 |
| rattus_norvegicus | Cgm4 | ENSRNOG00000062787 |
| rattus_norvegicus | LOC102557319 | ENSRNOG00000071114 |
Paralogs (24): CEACAM21 (ENSG00000007129), CEACAM1 (ENSG00000079385), CEACAM6 (ENSG00000086548), CEACAM4 (ENSG00000105352), CEACAM5 (ENSG00000105388), PSG8 (ENSG00000124467), CEACAM8 (ENSG00000124469), HEPACAM (ENSG00000165478), PSG6 (ENSG00000170848), CEACAM3 (ENSG00000170956), PSG9 (ENSG00000183668), CEACAM19 (ENSG00000186567), HEPACAM2 (ENSG00000188175), PSG5 (ENSG00000204941), CEACAM18 (ENSG00000213822), CEACAM16 (ENSG00000213892), VSTM5 (ENSG00000214376), PSG3 (ENSG00000221826), PSG7 (ENSG00000221878), PSG1 (ENSG00000231924), PSG2 (ENSG00000242221), PSG11 (ENSG00000243130), PSG4 (ENSG00000243137), CEACAM20 (ENSG00000273777)
Mouse-model phenotypes
Observed phenotypes of the mouse ortholog (MGI:1347251) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 51 distinct phenotype terms.
| Mouse phenotype (MP) | Records |
|---|---|
| increased circulating insulin level | 2 |
| decreased mean corpuscular hemoglobin concentration | 2 |
| decreased susceptibility to Coronaviridae infection | 2 |
| increased leukocyte cell number | 1 |
| abnormal colon morphology | 1 |
| obese | 1 |
| polyphagia | 1 |
| increased circulating HDL cholesterol level | 1 |
| decreased litter size | 1 |
| abnormal coat/hair pigmentation | 1 |
| abnormal glucose homeostasis | 1 |
| decreased susceptibility to viral infection | 1 |
| abnormal T cell physiology | 1 |
| increased mean platelet volume | 1 |
| decreased circulating triglyceride level | 1 |
| abnormal cytokine secretion | 1 |
| decreased circulating chloride level | 1 |
| increased insulin secretion | 1 |
| increased lean body mass | 1 |
| increased incidence of tumors by chemical induction | 1 |
| abnormal vascular wound healing | 1 |
| decreased energy expenditure | 1 |
| decreased T cell number | 1 |
| decreased T cell proliferation | 1 |
| decreased circulating cholesterol level | 1 |
+26 more (showing top 25).
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| CEACAM4 | protein-coding | 1089 |
| CEACAM3 | protein-coding | 1084 |
| CEACAM6 | protein-coding | 4680 |
| CEACAM5 | protein-coding | 1048 |
Protein
Protein identifiers
Cell adhesion molecule CEACAM7 — Q14002 (reviewed: Q14002)
Alternative names: Carcinoembryonic antigen CGM2, Carcinoembryonic antigen-related cell adhesion molecule 7
All UniProt accessions (2): Q14002, A0A0A0MTT6
UniProt curated annotations — full annotation on UniProt →
Subunit / interactions. Homodimer.
Subcellular location. Cell membrane. Apical cell membrane.
Tissue specificity. Expressed in columnar epithelial cells of the colon (at protein level). Strongly down-regulated in colonic adenocarcinomas.
Similarity. Belongs to the immunoglobulin superfamily. CEA family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q14002-1 | 2a | yes |
| Q14002-2 | 2b |
RefSeq proteins (2): NP_001278414, NP_008821 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR003599 | Ig_sub | Domain |
| IPR007110 | Ig-like_dom | Domain |
| IPR013106 | Ig_V-set | Domain |
| IPR013783 | Ig-like_fold | Homologous_superfamily |
| IPR036179 | Ig-like_dom_sf | Homologous_superfamily |
| IPR050831 | CEA_cell_adhesion | Family |
Pfam: PF07686, PF13927
UniProt features (33 total): strand 8, glycosylation site 7, sequence variant 3, sequence conflict 3, helix 3, domain 2, signal peptide 1, chain 1, disulfide bond 1, splice variant 1, propeptide 1, turn 1, lipid moiety-binding region 1
Structure
Experimental structures (PDB)
1 structures by resolution:
| PDB | Title | Method | Resolution (Å) |
|---|---|---|---|
| 4Y89 | Crystal structure of the N-terminal domain of CEACAM7 | X-RAY DIFFRACTION | 1.47 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q14002-F1 | 84.92 | 0.69 |
Human Protein Atlas
Protein class: Predicted membrane proteins
Protein evidence: Evidence at protein level
Subcellular location (HPA, imaging): plasma membrane; cytosol
Antibody reliability (HPA): IH enhanced · IF supported
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (1)
| Type | Positions |
|---|---|
| Gpi-anchor amidated serine | 242 |
Disulfide bonds (1)
| Type | Positions |
|---|---|
| Disulfide bond | 168–216 |
Glycosylation sites (7)
| Type | Positions |
|---|---|
| N-linked (glcnac…) asparagine | 174, 183, 198, 57, 85, 105, 112 |
Function
Pathways and Gene Ontology
Reactome pathways
1 curated (TAS) of 3; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
3 pathways:
| ID | Pathway | Evidence |
|---|---|---|
| R-HSA-163125 | Post-translational modification: synthesis of GPI-anchored proteins | curated |
| R-HSA-392499 | Metabolism of proteins | — |
| R-HSA-597592 | Post-translational protein modification | — |
MSigDB gene sets: 88 (showing top):
GOCC_CELL_SURFACE, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, GOCC_APICAL_PLASMA_MEMBRANE, MODULE_113, SABATES_COLORECTAL_ADENOMA_DN, GOCC_APICAL_PART_OF_CELL, GOCC_SIDE_OF_MEMBRANE, GOCC_PLASMA_MEMBRANE_REGION, GOMF_KINASE_BINDING, GOMF_PROTEIN_TYROSINE_KINASE_BINDING, DODD_NASOPHARYNGEAL_CARCINOMA_DN, REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, RICKMAN_HEAD_AND_NECK_CANCER_E, BOSCO_EPITHELIAL_DIFFERENTIATION_MODULE, REACTOME_POST_TRANSLATIONAL_MODIFICATION_SYNTHESIS_OF_GPI_ANCHORED_PROTEINS
GO Biological Process (2): regulation of immune system process (GO:0002682), signal transduction (GO:0007165)
GO Molecular Function (1): protein tyrosine kinase binding (GO:1990782)
GO Cellular Component (5): extracellular region (GO:0005576), plasma membrane (GO:0005886), cell surface (GO:0009986), apical plasma membrane (GO:0016324), side of membrane (GO:0098552)
Reactome top-level categories
2 top-level categories:
| Category | Pathways |
|---|---|
| Post-translational protein modification | 1 |
| Metabolism of proteins | 1 |
GO top-level categories
14 GO namespaces:
| Category | Terms |
|---|---|
| cellular anatomical structure | 3 |
| membrane | 2 |
| immune system process | 1 |
| regulation of biological process | 1 |
| cell communication | 1 |
| cellular process | 1 |
| signaling | 1 |
| regulation of cellular process | 1 |
| cellular response to stimulus | 1 |
| protein kinase binding | 1 |
| cell periphery | 1 |
| apical part of cell | 1 |
| plasma membrane region | 1 |
| leaflet of membrane bilayer | 1 |
Experimentally-supported GO annotations
GO terms backed by direct experimental evidence (ECO experimental codes) — 2 of 8 annotations. The rest are phylogenetic / computational / electronic (IEA).
2 experimentally-supported GO terms:
| GO term | NS | Evidence |
|---|---|---|
| apical plasma membrane | CC | direct assay |
| plasma membrane | CC | direct assay |
Protein interactions and networks
STRING
showing 15 of 490 interactions by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CEACAM7 | CYP2A13 | Q16696 | 560 |
| CEACAM7 | CYP2A7 | P20853 | 539 |
| CEACAM7 | CYP2A6 | P00190 | 451 |
| CEACAM7 | ZNF574 | Q6ZN55 | 426 |
| CEACAM7 | CD177 | Q8N6Q3 | 396 |
| CEACAM7 | CEACAM19 | Q7Z692 | 386 |
| CEACAM7 | GRB14 | Q14449 | 370 |
| CEACAM7 | BCL10 | O95999 | 365 |
| CEACAM7 | CARD9 | Q9H257 | 363 |
| CEACAM7 | A1BG | P04217 | 360 |
| CEACAM7 | TCN1 | P20061 | 310 |
| CEACAM7 | DSC2 | Q02487 | 306 |
| CEACAM7 | OTOP2 | Q7RTS6 | 303 |
| CEACAM7 | GUCA2A | Q02747 | 300 |
| CEACAM7 | ZNF526 | Q8TF50 | 299 |
IntAct
Human interaction partners of CEACAM7 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
4 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| CEACAM1 | physical association | 0.400 | 1 |
| CEACAM6 | physical association | 0.400 | 1 |
| GPC1 | physical association | 0.400 | 1 |
| PBRM1 | physical association | 0.400 | 1 |
BioGRID (7 interactions; top human partners by supporting records): CEACAM1 (Reconstituted Complex), CEACAM6 (Reconstituted Complex), GPC1 (Affinity Capture-MS), PBRM1 (Affinity Capture-MS), PSG3 (Negative Genetic), PSG6 (Negative Genetic)
Disease & clinical
Genetic variants
Variant evidence for CEACAM7: 47 ClinVar records (0 pathogenic / likely pathogenic).
ClinVar
47 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 41 |
| Likely benign | 3 |
| Benign | 0 |
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 29 predictions of 360):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| 19:41674761 | acceptor_gain | 1.0000 | |
| 19:41684066 | acceptor_gain | 0.9900 | |
| 19:41688100–41688101 | donor_loss | 0.9900 | 5 |
| 19:41683780 | donor_loss | 0.9800 | 2 |
| 19:41683783–41683784 | donor_loss | 0.9800 | 5 |
| 19:41686854 | donor_loss | 0.9800 | |
| 19:41686857–41686858 | donor_loss | 0.9800 | 5 |
| 19:41687222–41687223 | acceptor_loss | 0.9800 | 6 |
| 19:41677509 | acceptor_gain | 0.9700 | |
| 19:41683779–41683780 | donor_loss | 0.9700 | 2 |
AlphaMissense
283 missense substitutions predicted likely pathogenic (of 1,724 scored), across 99 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:
| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
|---|---|---|---|
| D117 | 8 | 0.857 | 0.924 |
| C168 | 7 | 0.963 | 0.982 |
| W67 | 7 | 0.956 | 0.992 |
| C216 | 7 | 0.944 | 0.983 |
| W179 | 7 | 0.919 | 0.982 |
| D210 | 7 | 0.704 | 0.790 |
| S227 | 6 | 0.935 | 0.979 |
| G93 | 6 | 0.934 | 0.970 |
| G70 | 6 | 0.862 | 0.938 |
| P42 | 6 | 0.735 | 0.828 |
| Y121 | 5 | 0.910 | 0.980 |
| F139 | 5 | 0.898 | 0.951 |
| Y68 | 5 | 0.896 | 0.960 |
| Y214 | 5 | 0.878 | 0.963 |
| P148 | 5 | 0.772 | 0.912 |
| K69 | 5 | 0.768 | 0.923 |
| G48 | 5 | 0.743 | 0.872 |
| G81 | 4 | 0.903 | 0.931 |
| G106 | 4 | 0.897 | 0.949 |
| I79 | 4 | 0.856 | 0.939 |
HPA cancer prognostics
RNA cancer specificity: Cancer enhanced (Colon Adenocarcinoma, Rectum Adenocarcinoma)
Disease associations
OMIM: gene MIM:619160 | disease phenotypes:
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (CPIC guideline: no)
CTD chemical–gene interactions
13 total (human), top 13 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Nickel | decreases expression | 2 |
| ethyl-p-hydroxybenzoate | decreases expression | 1 |
| sodium arsenite | decreases expression | 1 |
| 1,2-dielaidoylphosphatidylethanolamine | decreases expression | 1 |
| Zoledronic Acid | increases expression | 1 |
| Air Pollutants | increases expression, increases abundance | 1 |
| Benzo(a)pyrene | affects methylation | 1 |
| Estradiol | decreases expression | 1 |
| Malathion | decreases expression | 1 |
| Ozone | increases abundance, increases expression | 1 |
| Silicon Dioxide | decreases expression | 1 |
| Tobacco Smoke Pollution | affects expression | 1 |
| Tretinoin | increases expression | 1 |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.